Supreme Court Lets Merck Loss In Fosamax Case Stand

Law360, New York (October 17, 2005, 12:00 AM EDT) -- In a setback for Merck & Co., the U.S. Supreme Court has rejected the company’s appeal of a decision that shaved a decade off the patent for blockbuster osteoporosis drug Fosamax.

The decision lets stand a ruling by the U.S. Court of Appeals for the Federal Circuit that the patent on the once-weekly osteoporosis drug Fosamax will expire in February 2008, a decade earlier than expected.

The court denied Merck's appeal without comment. Chief Justice John Roberts and Justices Sandra Day O'Connor and Stephen Breyer had...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.